Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | ITGAL | P20701 | 1/20 | 0.41 |
| ▸ | TAS2R8 | Q9NYW2 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 5/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11569756 | 0.76 | ELANE (0.61) | ITGALELANEALDH1A1ATMCYP1A2 | |
| SCHEMBL13879502 | 0.70 | ITGAL (0.61) | ITGALELANEALDH1A1SMN1; SMN2 | |
| SCHEMBL13879517 | 0.70 | ITGAL (0.51) | ITGALELANEALDH1A1MEN1KMT2A | |
| SCHEMBL13879533 | 0.70 | ITGAL (0.76) | TSHRITGALELANEATM | |
| SCHEMBL13879524 | 0.70 | ALDH1A1 (0.53) | TSHRGAAALDH1A1MEN1KMT2A | |
| SCHEMBL13879378 | 0.69 | ITGAL (0.44) | ITGALELANEALDH1A1ATM | |
| SCHEMBL13879591 | 0.68 | MGLL (0.47) | ITGALELANEALDH1A1MEN1KMT2A | |
| SCHEMBL13879409 | 0.68 | ITGAL (0.49) | TSHRITGALGAAELANEALDH1A1 | |
| SCHEMBL13879551 | 0.68 | ITGAL (0.62) | ITGALELANEMEN1KMT2AHTT | |
| SCHEMBL13879546 | 0.68 | ITGAL (0.41) | TSHRITGALGAAELANEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | TSHR 4851/4885ITGAL 4495/4885TAS2R8 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.